KOSPI Cools 3.6% After Historic Rally as Samsung and SK Hynix Lead Profit-Taking

The Quick Take

• KOSPI opened 3.6% lower as Samsung shed 7.62% and SK Hynix fell 7.04% in profit-taking after historic July surge
• Foreign and institutional investors sold ₩1.18T combined while retail investors absorbed ₩1.15T net
• Ingenia Therapeutics completed IPO subscription for August 18 KOSDAQ listing to fund CKD drug development

South Korea's KOSPI experienced dramatic swings following an unprecedented 17.91% single-day surge at the end of July, with the index opening 3.6% lower at 6,358.27 on August 3 as profit-taking set in after the historic rally. Samsung Electronics fell 7.62% to trade in the ₩240,000 range, while SK Hynix declined 7.04%, with short-term profit realization pressure dominating after both stocks logged extraordinary prior-session gains — SK Hynix had hit its upper daily limit while Samsung surged over 26%. Securities analysts characterize the pullback as a healthy cooling of market overheating rather than a trend reversal.

Foreign investors and institutions were net sellers on August 3, with foreigners and institutions unloading approximately ₩1.05 trillion and ₩127 billion respectively, while individual retail investors absorbed ₩1.15 trillion in net purchases — a capital flow pattern that underscores the persistent divergence between institutional profit-taking and retail FOMO-driven accumulation. In parallel, biotech company Ingenia Therapeutics completed its public offering subscription ahead of an August 18 KOSDAQ listing, having raised capital for its chronic kidney disease drug IGT-303 in partnership with Harvard Medical School and US pharma giant MSD, demonstrating that the IPO market remains open for clinical-stage biotech even amid broader index volatility.

The KOSPI's forward trajectory hinges on whether the memory semiconductor sector — specifically Samsung and SK Hynix — can sustain the fundamental thesis that drove the original rally: recovery in DRAM and HBM pricing tied to AI infrastructure buildout. Watch Micron's US results and TSMC's forward guidance as leading indicators for Korean chip exporters. For Ingenia Therapeutics, the August 18 KOSDAQ listing date and early trading volume will signal market appetite for early-clinical biotech. The macro variable is US-Korea trade policy: any escalation of tariff tensions around Korean semiconductor exports would undermine the recovery thesis even if memory pricing fundamentals remain supportive.

Synthesized from 2 sources.